Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. - Wikidata - wikimedia - TriplyDB

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.

http://www.wikidata.org/entity/Q45885739

about

shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications Adenovirus vectors for gene therapy, vaccination and cancer gene therapy Oncolytic adenovirus-mediated therapy for prostate cancer Role of microRNAs in hepatocellular carcinoma: a clinical perspective Trial Watch:: Oncolytic viruses for cancer therapy Cancer vaccines Virotherapy: cancer gene therapy at last?Trial Watch-Oncolytic viruses and cancer therapy Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity Oncolytic immunotherapy: where are we clinically?Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.Classification of current anticancer immunotherapies Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors Polymeric oncolytic adenovirus for cancer gene therapy.Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.A century of oncolysis evolves into oncolytic immunotherapy.Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Trial watch: Oncolytic viruses for cancer therapy Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Oncolytic viruses and their application to cancer immunotherapy Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Gene therapy and imaging in preclinical and clinical oncology: recent developments in therapy and theranostics.The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.Applications of coxsackievirus A21 in oncology

P2860

Q26765364-3AC3108B-177E-49FC-9C88-0366CEAABCD5 Q26775030-3C9F9623-005A-4622-A7EE-0639860E7043 Q26776553-529A676D-759C-4313-ABD9-27B1A3EB1CCF Q27001601-94177B5B-AB46-4A26-912D-D67098836E8B Q27004796-9C3E0C6E-3046-4F65-8670-7FD872A1F534 Q27014034-46507945-FFB0-4201-8A94-03B31DE2BB8C Q27021951-B3316695-E4B0-4D33-8627-9D261589CAD7 Q27024438-63069175-320F-43F4-830B-2B7379FE02DF Q28066228-603D2E63-1EA8-4DFF-B90B-85BCCEB3D5C0 Q28072347-BBCC7216-63FD-4886-BF8D-270ECE75B8D9 Q30899557-FCD597A5-2AFE-4D25-AE0C-E0A4A2F501BA Q33635033-48D33662-1ED0-43C8-A035-CA2496E279AA Q33670728-B7930D9F-0BB7-4C7F-B620-82CE833C1372 Q34405325-ECA0BD98-3174-4842-AB2B-8B9F0B6B24FC Q34426949-C28C859D-2A71-4DA6-9035-30D1EF8F8E49 Q35149637-C12131AC-3497-42DD-B87E-CA2A73799994 Q35176800-3CA3711D-1865-4911-B7BC-A137E3F44E53 Q35506253-570AE628-7613-4767-B59F-72D9903C47D8 Q35594838-61237DAE-BD59-48A7-B7CB-0CAE1809B23C Q35653264-F8E2CBD1-0A64-40DF-88A2-E0C338D63D9E Q36344901-1F14038B-30B2-45C7-A46A-C8691BF1F2B7 Q36582785-85C0A471-18DE-43F6-8B3D-59935FDC8523 Q36664229-D4666E3D-4B65-42EB-843E-BB2B6A646DCA Q36710972-4666DE6B-66E0-4109-A517-FA2D0C751AF5 Q36710991-9F5C0AC9-FE7A-4446-A447-9C627EE2C7D2 Q36757131-0A6E594F-2228-4DA1-8F7F-59CC78967A6E Q36766032-82AA680E-6A28-4C0D-B216-EAA1AFBE7DA0 Q37028023-4BD0FA19-1A5C-413E-A98D-5D8108003AE3 Q37152107-3730B8AE-B602-4FB9-8660-391E726458BD Q37448016-EABD96AF-487F-48CB-AA53-30975663FCB7 Q37707676-6A64A400-A028-48D4-AE44-AC5326CE9A79 Q38193589-CEDEA500-8334-44C7-A1FE-417B72FEFC0B Q38194135-92DEEAC2-22D1-488A-A086-D990B34FC72A Q38207011-19DA61FF-D47B-4D9F-80CE-8DB6FE3DD4C1 Q38223419-04A775E3-C47F-4149-B5A3-4CDFBC036F43 Q38241666-D36F0A70-4CDC-4491-9C60-D9E86172573C Q38297124-561B2E59-CB34-43A9-9FA7-7949E819871F Q38357137-7F5DA53B-C44E-4BBE-842F-69C1E86B4493 Q38534285-4BFC75F0-94DB-47AB-AEF8-0AD1FAB8E10D Q38564325-E6A28E8D-E91B-4C17-A443-825681B40782

P2860

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.

http://www.wikidata.org/entity/Q45885739

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Antiviral and antitumor T-cell ...... F-coding oncolytic adenovirus.

@en

Antiviral and antitumor T-cell ...... F-coding oncolytic adenovirus.

@nl

type

label

Antiviral and antitumor T-cell ...... F-coding oncolytic adenovirus.

@en

Antiviral and antitumor T-cell ...... F-coding oncolytic adenovirus.

@nl

prefLabel

Antiviral and antitumor T-cell ...... F-coding oncolytic adenovirus.

@en

Antiviral and antitumor T-cell ...... F-coding oncolytic adenovirus.

@nl

P1433

Q45885739-BA9066A3-BDB4-496C-A436-29D28A9382F3

P1476

Q45885739-C6CF68EF-49DC-49C8-ADAD-73EB58F149D3

P2093

Q45885739-123D4CC5-5780-4A00-80C3-9C7F1B6DBB93

Q45885739-272FD6BE-EF0E-47BD-9405-4A485BC3A62C

Q45885739-2A813060-4645-4CB9-B003-FF412C640B27

Q45885739-331ADCCA-A823-492E-A88C-45B052FBE2E3

Q45885739-367F98AE-E9F4-4158-99B7-08214A6A5D19

Q45885739-486C47AD-D690-4FCC-BB1A-94560EF93F12

Q45885739-7C016EBA-D22B-4E1D-BA42-0C1E4F7BC70A

Q45885739-C3A3DFF9-A21A-4958-80FE-337B73F4FBEC

Q45885739-D4E90F46-695D-41B6-A252-2954BEE5A0C1

Q45885739-DB52599E-8D11-4367-9E15-AC4DE17D2EDD

P304

Q45885739-2D9D83EE-9844-4F82-BBA4-C711AA214EB6

P31

Q45885739-8F75743B-6A50-4A83-9BE3-D186C8032FFE

P356

Q45885739-9CECDE55-99CF-425C-AF9B-24E0B4F7F01B

P407

Q45885739-7B87D51A-5A67-49C9-92D8-4FD879EFB3AD

P433

Q45885739-22D8CDC6-78F1-4277-AB65-74CC6E6AB6DB

P478

Q45885739-0EC5ACA8-5093-4FCC-A2BB-CAE7662F325C

P50

Q45885739-140F89E0-E639-40E4-B44E-1F1BF81ADC67

Q45885739-3CFD8A8B-9D5C-43CE-B097-430F9375E90C

Q45885739-7F5B079F-A0F0-4AC7-B1AB-6AE72988714B

Q45885739-91874FD9-5121-48CD-AA96-6DBAD7D9FAFC

Q45885739-C56CFD0F-3B41-4142-86DD-53CEAC69A16A

Q45885739-FFED4BF5-A890-4402-9174-8B7C2212A47F

P577

Q45885739-5EAE22BD-C822-4F2A-A444-EDC545DE2AB3

P698

Q45885739-49642ED8-CE1F-4547-953C-4B1924BE4C17

P921

Q45885739-9F784C66-4C2B-4258-ACCC-61B5110FF2D4

Q45885739-A0F17B82-A1D2-472A-9292-E45BD59CE882

Q45885739-E52FD6B0-249F-4E75-9068-08ECFBB779E3

P356

1078-0432.CCR-12-2546

P1433

Clinical Cancer Research

P1476

Antiviral and antitumor T-cell ...... F-coding oncolytic adenovirus.

@en

P2093

Anniina Koski

http://www.w3.org/2001/XMLSchema#string

Ilkka Liikanen

http://www.w3.org/2001/XMLSchema#string

Kaarina Partanen

http://www.w3.org/2001/XMLSchema#string

Kalevi Kairemo

http://www.w3.org/2001/XMLSchema#string

Leena Laasonen

http://www.w3.org/2001/XMLSchema#string

Lotta Kangasniemi

http://www.w3.org/2001/XMLSchema#string

Petri Nokisalmi

http://www.w3.org/2001/XMLSchema#string

Raita Heiskanen

http://www.w3.org/2001/XMLSchema#string

Saila Pesonen

http://www.w3.org/2001/XMLSchema#string

Sari Pesonen

http://www.w3.org/2001/XMLSchema#string

P304

2734-2744

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-2546

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Akseli Hemminki

Vincenzo Cerullo

P577

2013-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23493351

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus